Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hyperphosphataemia therapy - Acologix

Drug Profile

Research programme: hyperphosphataemia therapy - Acologix

Alternative Names: AC-200; Matrix extracellular phosphoglycoprotein - Acologix; MEPE; Phosphatonin

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acologix; University College London
  • Developer Acologix
  • Class Glycoproteins
  • Mechanism of Action Extracellular matrix protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hyperphosphataemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperphosphataemia in USA (IV, Injection)
  • 19 Nov 2008 Pharmacodynamics data from a preclinical trial in a rat model of chronic kidney failure released by Acologix
  • 22 Jun 2006 Phosphatonin (AC 200) has been licensed to Toray Industries in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top